sg 209 has been researched along with quinoxalines in 1 studies
Studies (sg 209) | Trials (sg 209) | Recent Studies (post-2010) (sg 209) | Studies (quinoxalines) | Trials (quinoxalines) | Recent Studies (post-2010) (quinoxalines) |
---|---|---|---|---|---|
15 | 0 | 3 | 9,887 | 625 | 3,095 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Di Girolamo, N; Heywood, GJ; Thomas, PS; Wei, XM | 1 |
1 other study(ies) available for sg 209 and quinoxalines
Article | Year |
---|---|
Nicorandil inhibits the release of TNFalpha from a lymphocyte cell line and peripheral blood lymphocytes.
Topics: B-Lymphocytes; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glyburide; Herpesvirus 4, Human; Humans; Immunoglobulin G; Leukocytes, Mononuclear; Niacinamide; Nicorandil; Nitric Oxide Synthase; Nitroprusside; omega-N-Methylarginine; Oxadiazoles; Pinacidil; Potassium Channels; Quinoxalines; Tetradecanoylphorbol Acetate; Tumor Necrosis Factor-alpha | 2003 |